The University of California, San Francisco (UCSF) has been awarded a $814,790 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). This grant supports research to investigate the immune mechanisms underlying the clearance of the hepatitis B virus (HBV) surface antigen, which represents a clinical cure for chronic HBV infection. By studying samples from HBV patients who have successfully cleared the surface antigen, the researchers aim to uncover new biomarkers and identify potential therapeutic approaches to facilitate HBV clearance in a broader population of chronic HBV patients. This 5-year research project leverages UCSF's expertise in HBV immunology and builds on prior clinical studies conducted at UCSF and other institutions. The findings have the potential to significantly advance the understanding and treatment of chronic HBV, a major global health issue.
Generated 2/25/25, 1:52 AM